SCHEMBL16455485

SCHEMBL16455485

CC(C)c1ccccc1-n1nc(C(=O)O)c(Cl)c1-c1nnc(-c2cccc(S(C)(=O)=O)c2)o1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA13 Q8N1Q1 2/20 0.39
HSP90AA1 P07900 3/20 0.39
ATR Q13535 1/20 0.39
LMNA P02545 2/20 0.38
RXRA P19793 5/20 0.37
NR1H2 P55055 5/20 0.37
NR1H3 Q13133 5/20 0.37
MAOB P27338 2/20 0.37
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSP90B1 P14625 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16455239 0.91 RXRA (0.43) ALDH1A1NPC1RAB9ACA1CA2
SCHEMBL16455486 0.90 ALDH1A1 (0.39) ALDH1A1NPC1RAB9ACA1CA2
SCHEMBL16455382 0.89 RXRA (0.47) ALDH1A1NPC1RAB9ACA1CA2
SCHEMBL16455244 0.89 NR1H2 (0.42) ALDH1A1NPC1RAB9ACA1CA2
SCHEMBL16452547 0.88 NPC1 (0.46) ALDH1A1NPC1RAB9ACA1CA2
SCHEMBL16455245 0.87 HSP90AA1 (0.36) ALDH1A1NPC1RAB9ACA1CA2
SCHEMBL16455300 0.86 S1PR1 (0.44) NPC1RAB9ACA1CA2CA9
SCHEMBL16455255 0.85 NR1H2 (0.48) ALDH1A1NPC1RAB9ACA1CA2
SCHEMBL16455644 0.84 NR1H2 (0.40) HSP90AA1RXRANR1H2NR1H3HSP90B1
SCHEMBL16455490 0.82 NR1H2 (0.40) ALDH1A1NPC1RAB9ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210101895-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS RALEXAR THERAPEUTICS, INC. 2021-04-08 US disclosed
EP-3441390-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS Ralexar Therapeutics, Inc. (US) 2019-02-13 EP disclosed
US-20170334897-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions ALEXAR THERAPEUTICS, INC. 2017-11-23 US disclosed
US-9637481-B2 Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions RALEXAR THERAPEUTICS, INC. (US) 2017-05-02 US disclosed
US-20150152094-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS RALEXAR THERAPEUTICS, INC. 2015-06-04 US disclosed
US-8987318-B2 Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions ALEXAR THERAPEUTICS, INC. (US) 2015-03-24 US disclosed
US-20150045399-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions ALEXAR THERAPEUTICS, INC. (US) 2015-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045399-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions NR1H2, NR1H3, RXRA ALDH1A1 1118/4885NPC1 93/4885RAB9A 3987/4885
US-20170334897-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions NR1H2, NR1H3, RXRA ALDH1A1 1166/4885NPC1 89/4885RAB9A 4063/4885
US-20210101895-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS NR1H2, NR1H3, RXRG ALDH1A1 1080/4885NPC1 102/4885RAB9A 4034/4885
US-20150152094-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS NR1H2, NR1H3, RXRA ALDH1A1 1118/4885NPC1 93/4885RAB9A 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.